- Home
- APRE vs PIRS Comparison
APRE vs PIRS Comparison
Compare APRE & PIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- PIRS
- Stock Information
- Founded
- APRE 2006
- PIRS 2001
- Country
- APRE United States
- PIRS United States
- Employees
- APRE N/A
- PIRS N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- PIRS Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- PIRS Health Care
- Exchange
- APRE Nasdaq
- PIRS Nasdaq
- Market Cap
- APRE 21.3M
- PIRS 22.4M
- IPO Year
- APRE 2019
- PIRS N/A
- Fundamental
- Price
- APRE $2.92
- PIRS $15.93
- Analyst Decision
- APRE Strong Buy
- PIRS
- Analyst Count
- APRE 2
- PIRS 0
- Target Price
- APRE $15.50
- PIRS N/A
- AVG Volume (30 Days)
- APRE 13.3K
- PIRS 37.6K
- Earning Date
- APRE 11-07-2024
- PIRS 11-13-2024
- Dividend Yield
- APRE N/A
- PIRS N/A
- EPS Growth
- APRE N/A
- PIRS N/A
- EPS
- APRE N/A
- PIRS N/A
- Revenue
- APRE $1,310,839.00
- PIRS $1,352,000.00
- Revenue This Year
- APRE $116.72
- PIRS N/A
- Revenue Next Year
- APRE N/A
- PIRS N/A
- P/E Ratio
- APRE N/A
- PIRS N/A
- Revenue Growth
- APRE 130.31
- PIRS N/A
- 52 Week Low
- APRE $2.15
- PIRS $6.20
- 52 Week High
- APRE $8.85
- PIRS $22.32
- Technical
- Relative Strength Index (RSI)
- APRE 34.50
- PIRS 43.29
- Support Level
- APRE $2.87
- PIRS $15.15
- Resistance Level
- APRE $3.35
- PIRS $16.97
- Average True Range (ATR)
- APRE 0.32
- PIRS 0.72
- MACD
- APRE -0.12
- PIRS -0.08
- Stochastic Oscillator
- APRE 4.50
- PIRS 30.75
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About PIRS Pieris Pharmaceuticals Inc.
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.